NCT06569823View on ClinicalTrials.gov

Safety and Immunogenicity of an Investigational Herpes Zoster Vaccine (Z-1018) Compared to Shingrix® in Healthy Adults

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

440

Participants

Timeline

Start Date

June 17, 2024

Primary Completion Date

September 30, 2026

Study Completion Date

September 30, 2026

Conditions
ShinglesHerpes ZosterVaccine-Preventable Diseases
Interventions
BIOLOGICAL

Z-1018

Formulation for injection

BIOLOGICAL

Shingrix

Formulation for injection

Trial Locations (1)

2100

RECRUITING

Northern Beaches Clinical Research, Brookvale

Sponsors
All Listed Sponsors
lead

Dynavax Technologies Corporation

INDUSTRY

NCT06569823 - Safety and Immunogenicity of an Investigational Herpes Zoster Vaccine (Z-1018) Compared to Shingrix® in Healthy Adults | Biotech Hunter | Biotech Hunter